Connect Biopharma (CNTB) Competitors $2.07 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.07 0.00 (0.00%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. UPXI, ATYR, REPL, SVRA, SNDL, CMPS, MBX, RGNX, KMDA, and PVLAShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Upexi (UPXI), aTyr Pharma (ATYR), Replimune Group (REPL), Savara (SVRA), SNDL (SNDL), COMPASS Pathways (CMPS), MBX Biosciences (MBX), REGENXBIO (RGNX), Kamada (KMDA), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors Upexi aTyr Pharma Replimune Group Savara SNDL COMPASS Pathways MBX Biosciences REGENXBIO Kamada Palvella Therapeutics Upexi (NASDAQ:UPXI) and Connect Biopharma (NASDAQ:CNTB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do insiders & institutionals hold more shares of UPXI or CNTB? 5.7% of Upexi shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 31.6% of Upexi shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to UPXI or CNTB? In the previous week, Upexi had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Upexi and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.46 beat Upexi's score of 0.44 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer UPXI or CNTB? Upexi currently has a consensus price target of $15.50, suggesting a potential upside of 156.62%. Connect Biopharma has a consensus price target of $7.00, suggesting a potential upside of 238.16%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is UPXI or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Connect Biopharma's return on equity of 0.00% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Upexi-135.86% -535.19% -122.94% Connect Biopharma N/A N/A N/A Which has more risk & volatility, UPXI or CNTB? Upexi has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Which has higher earnings and valuation, UPXI or CNTB? Connect Biopharma has higher revenue and earnings than Upexi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$26M20.76-$23.66MN/AN/AConnect Biopharma$26.03M4.42-$15.63MN/AN/A SummaryConnect Biopharma beats Upexi on 11 of the 15 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$115.01M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E RatioN/A7.0321.9724.23Price / Sales4.42314.42449.4898.71Price / CashN/A41.8536.4258.36Price / Book1.247.318.185.64Net Income-$15.63M-$54.43M$3.26B$265.68M7 Day Performance3.50%-0.01%1.15%2.51%1 Month Performance82.39%5.13%2.82%1.88%1 Year Performance95.28%10.24%28.41%24.00% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma2.6594 of 5 stars$2.07flat$7.00+238.2%+93.5%$115.01M$26.03M0.00110Short Interest ↑Gap UpUPXIUpexi3.6813 of 5 stars$5.02+9.1%$15.50+208.8%+23.2%$448.59M$26M0.00130ATYRaTyr Pharma2.0436 of 5 stars$5.02+6.8%$20.20+302.4%+194.4%$446.80MN/A-6.2053Earnings ReportUpcoming EarningsGap UpREPLReplimune Group4.7361 of 5 stars$5.71-24.9%$7.67+34.3%-40.4%$444.28MN/A-1.86210Trending NewsEarnings ReportUpcoming EarningsHigh Trading VolumeSVRASavara1.9973 of 5 stars$2.57-0.8%$5.60+117.9%-34.3%$444.19MN/A-5.3520Upcoming EarningsSNDLSNDL2.7817 of 5 stars$1.64-0.6%$4.00+143.9%-17.3%$430.95M$944.25M-6.072,516CMPSCOMPASS Pathways2.83 of 5 stars$4.60+6.0%$16.29+254.0%-36.9%$430.39MN/A-2.50120News CoverageAnalyst RevisionMBXMBX Biosciences2.704 of 5 stars$12.54-8.8%$37.57+199.6%N/A$419.14MN/A0.0036News CoverageAnalyst ForecastRGNXREGENXBIO3.9584 of 5 stars$8.33+1.7%$31.63+279.7%-34.4%$417.83M$83.33M-2.68370News CoverageEarnings ReportAnalyst ForecastKMDAKamada4.4084 of 5 stars$7.19-0.4%$13.00+80.8%+33.5%$413.50M$160.95M24.79360News CoveragePositive NewsUpcoming EarningsPVLAPalvella Therapeutics2.7168 of 5 stars$37.20+1.8%$52.22+40.4%N/A$411.43M$42.81M-3.07N/ANews CoverageUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies UPXI Competitors ATYR Competitors REPL Competitors SVRA Competitors SNDL Competitors CMPS Competitors MBX Competitors RGNX Competitors KMDA Competitors PVLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
